Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AqT-duocarmycin
- Development stage
- Preclinical
- Lead developer
- AqueaTether Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
AqT-duocarmycin is a specialized antibody-drug conjugate (ADC) payload developed by AqueaTether Therapeutics, a partner of CellMosaic. It utilizes the proprietary AqueaTether (AqT) technology to modify a duocarmycin analog, a potent cytotoxic small molecule. Duocarmycins function as DNA minor-groove alkylators; they bind specifically to the minor groove of DNA and alkylate the N3 position of adenine, leading to irreversible DNA damage, cell cycle arrest, and apoptosis. The AqT modification is designed to enhance the hydrophilicity and conjugation efficiency of the typically hydrophobic duocarmycin payload, allowing for the development of ADCs with improved pharmacological profiles. It is currently utilized as a platform asset for the construction of novel cancer therapeutics.
- Brand names
- AqT
- Other names
- AqT-Duocarmycin (platform payload)Duocarmycin AqT
02
Targets
DNA
Beyond the preview
Go deeper on AqT-duocarmycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AqT-duocarmycin.